AndreaBozzo/ceres-open-data-index huggingface dataset:
2010-2011 NSDUH State Estimates of Substance Use and Mental Disorders

This page presents the tables of State-specific tables of State estimates for 25 measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State by age group.
2010 State Profile — Nebraska

This state profile includes data from facilities in Nebraska that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Nebraska. In Nebraska, 115 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 5,326 clients in substance abuse treatment on March 31, 2010. The survey response rate in Nebraska was 91.9%.
List of Excluded Individuals and Entities

<p>Our objective is to ensure that providers who bill Federal health care programs do not submit claims for services furnished, ordered or prescribed by an excluded individual or entity.  The LEIE is updated monthly with all individuals and entities who have been excluded from participation in Federal health care programs.  Providers who bill Medicare, Medicaid, or other Federal health care programs must ensure that they know what individuals or entities are excluded and not bill for their services (e.g., a pharmacy should not bill Medicaid for a drug prescribed by an excluded physician nor for drugs dispensed by an excluded pharmacist).</p>
Compound 526004: 3-Hydroxyadipic acid, lacton, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(5-oxooxolan-2-yl)acetate. Molecular Formula: C9H16O4Si. Molecular Weight: 216.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526460: Propyl perfluoropentanoate

Chemical compound data from PubChem database. IUPAC Name: propyl 2,2,3,3,4,4,5,5,5-nonafluoropentanoate. Molecular Formula: C8H7F9O2. Molecular Weight: 306.13. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529199: Benzoic acid, 3,4,5-triiodo, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3,4,5-triiodobenzoate. Molecular Formula: C10H11I3O2Si. Molecular Weight: 571.99. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Acetazolamide

Acetazolamide is a generic prescription drug available as oral tablets in 125mg and 250mg strengths. It acts as a carbonic anhydrase inhibitor, commonly used to treat glaucoma, epilepsy, and altitude sickness by reducing fluid buildup in the body. Manufactured by ANI Pharmaceuticals, Inc. under FDA application ANDA210588. This information was generated using AI and is provided for informational and research purposes only.
National Directory of Drug and Alcohol Abuse Treatment Facilities - 2019

The National Directory of Drug and Alcohol Abuse Treatment Facilities - 2019 is a listing of federal, state, and local government facilities and private facilities that provide substance abuse treatment services. It includes treatment facilities that (1) are licensed, certified, or otherwise approved for inclusion in the Directory by their State Substance Abuse Agencies, and (2) responded to the 2018 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this Directory was provided by that facility in response to the 2018 N-SSATS. N-SSATS is conducted annually by the Substance Abuse and Mental Health Services Administration (SAMHSA).The Directory is ordered alphabetically by state, by city within each state, and by facility name within each city. Each facility listing includes codes that represent the services offered and other features of the facility, including codes that indicate services for hearing impaired and non-English-speaking clients. Codes are defined in a key shown on pages v-ix. Because the services offered by a particular facility may change over time, it is always a good idea to verify the information in this Directory when contacting a facility.
Simultaneous identification of

Background
          The glutathione S-transferase (GST) enzyme GSTP1 utilizes byproducts of oxidative stress. We previously showed that alleles of GSTP1 that encode the Ile105→Val105 substitution are associated with the asthma phenotypes of atopy and bronchial hyperresponsiveness (BHR). However, a further polymorphic site (Ala114→Val114) has been identified that results in the following alleles: GSTP1*A (wild-type Ile105→Ala114), GSTP1*B (Val105→Ala114), GSTP1*C (Val105→Val114) and GSTP1*D (Ile105→Val114).
        
        
          Methods
          Because full identification of GSTP1 alleles may identify stronger links with asthma phenotypes, we describe an amplification refractory mutation system (ARMS) assay that allows identification of all genotypes. We explored whether the GSTP1 substitutions influence susceptibility to asthma, atopy and BHR.
        
        
          Results
          Among 191 atopic nonasthmatic, atopic asthmatic and nonatopic nonasthmatic individuals, none had the BD, CD, or DD genotypes. GSTP1 BC was significantly associated with reduced risk for atopy (P = 0.031). Compared with AA, trend test analysis identified a significant decrease in the frequency of GSTP1 BC with increasing severity of BHR (P = 0.031). Similarly, the frequency of GSTP1 AA increased with increasing BHR.
        
        
          Conclusion
          These data suggest that GSTP1*B and possibly GSTP1*C are protective against asthma and related phenotypes.
Compound 529417: L-Fucitol pentaacetate

Chemical compound data from PubChem database. IUPAC Name: [(2S,3R,4S,5R)-2,3,4,5-tetraacetyloxyhexyl] acetate. Molecular Formula: C16H24O10. Molecular Weight: 376.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Types and frequency of preanalytical mistakes in the first Thai ISO 9002:1994 certified clinical laboratory, a 6 – month monitoring

Background
          Reliability cannot be achieved in a clinical laboratory through the control of accuracy in the analytical phase of the testing process alone. Indeed a "mistake" can be defined as any defect occuring during the testing process. In the analysis of clinical specimens, there are many possible preanalytical sources of error. Therefore, the application of quality system to laboratory testing requires total quality management throughout the laboratory process, including the preanalytical and postanalytical phases. ISO 9002:1994 is a model for quality assurance in production, installation, and servicing, which includes a number of clauses providing guidance for implementation in clinical laboratories. Our laboratory at King Chulalongkorn Memorial Hospital, the largest Thai Red Cross Society hospital, is the first clinical laboratory in Thailand with ISO 9002:1994 certified for the whole unit.
        
        
          Method
          In this study, we evaluated the frequency and types of preanalytical mistakes found in our laboratory, by monitoring specimens requested for laboratory analyses from both in-patient and out-patient divisions for 6 months.
        
        
          Result
          Among a total of 935,896 specimens for 941,902 analyses, 1,048 findings were confirmed as preanalytical mistakes; this was a relative frequency of 0.11 % (1,048/935,896). A total of 1,240 mistakes were identified during the study period. Comparing the preanalytical mistakes to other mistakes in the laboratory process monitored in the same setting and period, the distribution of mistakes was: preanalytical 84.52 % (1,048 mistakes), analytical 4.35 % (54 mistakes), and postanalytical 11.13 % (138 mistakes). Of 1,048 preanalytical mistakes, 998 (95.2%) originated in the care units. All preanalytical mistakes, except for 12 (1.15 %) relating to the laboratory barcode reading machine, were due to human error.
        
        
          Conclusion
          Most mistakes occurred before samples were analysed, either during sampling or preparation for analysis. This suggests that co-operation with clinicians and personnel outside the laboratory is still the key to improvement of laboratory quality.
The role of X-chromosome inactivation in female predisposition to autoimmunity

We propose that the phenomenon of X-chromosome inactivation in females may constitute a risk factor for loss of T-cell tolerance; specifically that skewed X-chromosome inactivation in the thymus may lead to inadequate thymic deletion. Using a DNA methylation assay, we have examined the X-chromosome inactivation patterns in peripheral blood from normal females (n = 30), female patients with a variety of autoimmune diseases (n = 167). No differences between patients and controls were observed. However, locally skewed X-chromsome inactivation may exist in the thymus, and therefore the underlying hypothesis remains to be disproved.
Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae

Background
          The continuous spread of penicillin-resistant pneumococci represents a permanent threat in the treatment of pneumococcal infections, especially when strains show additional resistance to quinolones. The main objective of this study was to determine a treatment modality impeding the emergence of quinolone resistance.
        
        
          Results
          Exposure of a penicillin-resistant pneumococcus to increasing concentrations of trovafloxacin or ciprofloxacin selected for mutants resistant to these drugs. In the presence of sub-inhibitory concentrations of vancomycin, development of trovafloxacin-resistance and high-level ciprofloxacin-resistance were prevented.
        
        
          Conclusions
          Considering the risk of quinolone-resistance in pneumococci, the observation might be of clinical importance.
Debate: Statins should be used in patients with heart failure

Treatment to prevent progression of heart failure has been targeted to reverse the consequences of heart failure and to a lesser extent the cause – the atherosclerotic plaque itself. Less than 50% of patients with heart failure are treated with lipid intervention. Heart failure (New York Heart Association [NYHA] functional classes I and II) is associated with an increase in low-density lipoproteins (LDL) and triglycerides while high-density lipoproteins (HDL) is lowered. In NYHA class IV, cholesterol is reduced due to depressed production in the liver. Although lipoproteins, especially LDL and HDL, may have some protective effect in binding and neutralising endotoxins released from the intestine during terminal heart failure, observational studies in patients with heart failure strongly suggest that lipid modification with statins may reduce progression of heart failure as well as reducing heart failure mortality.
Compound 529020: 1-Ethyl-3-methyl-5-propylbenzene

Chemical compound data from PubChem database. IUPAC Name: 1-ethyl-3-methyl-5-propylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The NSDUH Report: State Estimates of Adolescent Cigarette Use and Perceptions of Risk from Smoking: 2009 and 2010

This short report uses 2009 to 2010 National Survey on Drug Use and Health (NSDUH) to assess cigarette risk perception and cigarette use among adolescents aged 12 to 17 by State. Results are shown by State for 2002-2003 and 2009-2010.
Dependence, Abuse, and Treatment Tables (Standard Errors and P Values) - 5.1 to 5.56

These detailed tables present standard errors for totals and prevalence estimates of substance dependence/abuse and treatment need/receipt from the 2011 National Survey on Drug Use and Health (NSDUH). Substances examined include illicit drugs, marijuana, cocaine, heroin, hallucinogens, inhalants, and the nonmedical use of prescription-type pain relievers, tranquilizers, stimulants, and sedatives, and alcohol.Standard errors are provided by age group, gender, race/ethnicity, education level, employment status, and geographic area. Standard errors are provided for both 2011 and 2010.
Compound 527358: 18,22,26-Trimethyl-dotriacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 19,23,27-trimethyltritriacontanenitrile. Molecular Formula: C36H71N. Molecular Weight: 518.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
What you should know about PR3-ANCA: Structural aspects of antibodies to proteinase 3 (PR3)

Reactive antigenic epitopes on presumed autoantigens of biologic interest have been examined by many researchers. The central third complementarity-determining region (CDR3) residues of a human monoclonal anti-proteinase 3 (PR3) antibody contained many negatively charged aspartic acid residues, perhaps contributing to its reactivity with positively charged PR3 regions. Examination of four other human monoclonal anti-PR3 antibodies shows a number of negatively charged residues within their CDR3 regions. Mapping of segments of linear PR3-epitopes reacting with anti-neutrophil cytoplasmic antibodies (ANCA) demonstrated a preliminary estimate of structures contributing to antigenic determinants. T-cell epitopes on PR3 are reported in studies of chronic myeloid leukemia. These T-cell epitopes appear to be human leukocyte antigen (HLA) A2.1 restricted.
Compound 527533: 2-butan-2-yl-1H-pyrrole

Chemical compound data from PubChem database. IUPAC Name: 2-butan-2-yl-1H-pyrrole. Molecular Formula: C8H13N. Molecular Weight: 123.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Kit for the preparation of technetium tc 99m albumin aggregated

Pulmotech MAA is a prescription kit from Curium US LLC used to prepare Technetium Tc 99m Albumin Aggregated, a radioactive injectable for medical imaging via intraperitoneal or intravenous routes. It comes as a lyophilized powder for suspension, packaged in multi-dose vials. This information was generated using AI and is provided for informational and research purposes only.
Low-volume jet injection for intradermal immunization in rabbits

Background
          This study tested a low-volume (20–30 μl/20–30 μg DNA) jet injection method for intradermal delivery of a DNA vaccine. Jet injection offers the advantages of a needle-less system, low-cost, rapid preparation of the injected DNA solution, and a simple delivery system. More than one construct can be injected simultaneously and the method may be combined with adjuvants.
        
        
          Results
          Low-volume jet injection targeted delivery of a DNA solution exclusively to the dermis and epidermis of rabbits. A three injection series of plasmid DNA, encoding the Hepatitis B Surface Antigen stimulated a humoral immune response in 2/5 rabbits. One rabbit developed a significant rise in antibody titer after 1 injection and one following 2 injections. There were no significant differences between jet injection and particle bombardment in the maximal antibody titers or number of injections before response. A three injection series of the same plasmid DNA by particle bombardment elicited a significant rise in antibody titer in 3/5 rabbits. One rabbit developed antibody after 1 injection and two after 3 injections. In contrast, 0/5 rabbits receiving DNA by needle and syringe injection responded. In the jet injection and particle bombardment groups, gene expression levels in the skin did not predict response. While immune responses were similar, luciferase gene expression levels in the skin following particle bombardment were 10–100 times higher than jet injection.
        
        
          Conclusion
          Low-volume jet injection is a simple, effective methodology for intradermal DNA immunization.
Network PUF - PY2014

The Network PUF (Ntwrk-PUF) is one of the seven files that make up the Marketplace PUF. The Ntwrk-PUF contains issuer-level data identifying provider network URLs. These data either originate from the Network ID template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Patent AT-E400307-T1: [Translated] ENDOVASCULAR IMPLANT WITH THROMARCOGENIC COATING

An endovascular graft, e.g., having both an expandable stent portion and a stent cover portion positioned within and/or surrounding the expandable portion, the graft itself and/or a stent cover portion being coated with a bioactive agent adapted to promote initial thrombus formation, preferably followed by long term fibrous tissue in growth. The endovascular graft addresses concerns regarding endoleaking by permitting the graft to be deployed and used in a manner that promotes a short term hemostatic effect in the perigraft region. This short term effect can, in turn, be used to promote or permit long term fibrous tissue ingrowth. Particularly where the stent cover portion is prepared from a porous material selected from PET and ePTFE, the bioactive agent can include a thrombogenic agent such as collagen covalently attached in the form of a thin, conformal coating on at least the outer surface of the stent cover. An optimal coating of this type is formed by the activation of photoreaction groups provided by either the cover material itself, by the bioactive agent itself, and/or by a linking agent.
Patent AT-E400620-T1: [Translated] ANTIFOULING PAINT FOR SHIP HULLS AND METHOD FOR APPLYING SAME

A marine anti-bio-fouling coating 10, for application onto the surface of a marine article 12. The coating 10 comprises a self-levelling, self-curing epoxy resin primer adhesive 14, an adhesive modified epoxy resin binder adhesive 16 and granulated Copper Nickel alloy 18. When a coated marine article 12 is immersed in water a chemical reaction occurs between the water and the Copper Nickel alloy 18 which causes a film of a complex metal oxide 20 to form on the exterior surface of the layer of Copper Nickel alloy granules 18. The oxide film 20 forms an inhospitable environment to aquatic organisms and aquatic borers, thereby preventing bio-fouling occurring on the coated marine article. A method of applying the coating 10 to a marine article 12 is also provided.
Compound 525787: 4,5-Dimethyl-2-pentyloxazole

Chemical compound data from PubChem database. IUPAC Name: 4,5-dimethyl-2-pentyl-1,3-oxazole. Molecular Formula: C10H17NO. Molecular Weight: 167.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526640: 2,5-Di-O-Acetyl-1,4-Anhydro-3-O-methyl-L-fucitol

Chemical compound data from PubChem database. IUPAC Name: [5-(1-acetyloxyethyl)-4-methoxyoxolan-3-yl] acetate. Molecular Formula: C11H18O6. Molecular Weight: 246.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530686: 4-Ethylbenzoic acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl 4-ethylbenzoate. Molecular Formula: C19H24O2. Molecular Weight: 284.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401081-T1: [Translated] AMMONIUM SALTS OF ORNITHINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES

The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of N<delta>-acyl derivatives of N<alpha>(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic N<delta>-acyl derivatives of N<delta>-acyl derivatives of N<alpha>(4-amino-4-deoxypteroyl)-L-ornithine compounds.
Compound 527687: Butanoic acid, 3-chloro, 1-methylbutyl ester

Chemical compound data from PubChem database. IUPAC Name: pentan-2-yl 3-chlorobutanoate. Molecular Formula: C9H17ClO2. Molecular Weight: 192.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525193: Chloromethyl 2-chloroheptanoate

Chemical compound data from PubChem database. IUPAC Name: chloromethyl 2-chloroheptanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2013 CMHS Uniform Reporting System (URS) Tables for Michigan

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Michigan for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.